HURA: New U.S. Patent Broadens VISTA Inhibitor TBS-2025 to Bispecific Antibodies

What happened

TuHURA Biosciences announced that the USPTO issued a new patent broadening coverage for its VISTA inhibitor TBS-2025 to include bispecific and multi-specific antibodies across all human antibody classes. This development adds to the company's VISTA program, acquired through the Kineta merger, and complements its lead Phase 3 asset IFx-2.0 in Merkel cell carcinoma. While the patent extension could strengthen the intellectual property position around TBS-2025, it does not address the company's critical challenges: no product revenue, operating losses, and a disclosed need for substantial additional funding through at least late Q4 2025. The announcement is a routine IP update that may have limited near-term impact on the stock, as market focus remains on execution of the IFx-2.0 Phase 3 trial and securing financing. Overall, this news is a minor positive for the VISTA program's long-term optionality but does not alter the speculative, high-risk profile of the company.

Implication

For current holders, the broadened patent may offer some downside protection for the VISTA asset if TBS-2025 progresses, but it does not mitigate immediate liquidity or dilution risks. Given the company's cash runway extending only through late 2025, additional equity or debt raises are likely, which could pressure shares regardless of IP developments. Those considering a position should wait for clarity on the Phase 3 MCC trial's enrollment and interim data, as well as an updated financing plan. The patent's emphasis on bispecific formats could support future partnering discussions, but no such discussions have been disclosed. Overall, this news is unlikely to change the risk-reward calculus for all but the most speculative investors.

Thesis delta

The issuance of a broader patent for TBS-2025 slightly strengthens the intellectual property moat around the VISTA inhibitor, particularly for bispecific applications, but does not change the fundamental thesis that HURA is a high-risk, development-stage biotech with no revenue and a near-term capital need. The core value driver remains the IFx-2.0 Phase 3 trial in MCC under accelerated approval, and execution risk and financing overhang persists. Thus, while the patent adds optionality for the VISTA program, it does not justify a revision to the speculative/high-risk judgment.